FindTrial
Sign In

Application of Metronidazole-Containing Contrast Medium Prevents Post-ERCP Cholangitis in Patients with prior Liver Transplantation: A Randomized Control Study

Application of Metronidazole-Containing Contrast Medium Prevents Post-ERCP Cholangitis in Patients with prior Liver Transplantation: A Randomized Control Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16009533
Enrollment
Unknown
Registered
2016-10-21
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cholangitis

Interventions

experimental group:Metronidazole
control group:without metronidazole

Sponsors

Digestive Endoscopy Center, Department of Gastroenterology, Ruijin Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 95 Years

Inclusion criteria

Inclusion criteria: From November 2016 to March 2017, patients with prior liver transplantation underwent ERCP in our institute are included.

Exclusion criteria

Exclusion criteria: 1. under age; 2. pregnant women; 3. malignant disease; 4. allergic to the medicine of this study.

Design outcomes

Primary

MeasureTime frame
incidence of cholangitis;—

Countries

China

Contacts

Public ContactBiao Gong

Shanghai Ruijin Hospital

gongbiaosj@126.com+86 18801800616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026